Who are prednisone plus cyclophosphamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prednisone-plus-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

prednisone plus cyclophosphamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

prednisone plus cyclophosphamide (prednisone plus cyclophosphamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid plus alkylating agent combination. Area: Immunology / Oncology.

marketed Corticosteroid plus alkylating agent combination Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

prednisone plus cyclophosphamide (prednisone plus cyclophosphamide) — Guangdong Provincial People's Hospital. Prednisone suppresses immune and inflammatory responses while cyclophosphamide acts as an alkylating agent to kill rapidly dividing cells, together providing immunosuppression and cytotoxic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
prednisone plus cyclophosphamide TARGET	prednisone plus cyclophosphamide	Guangdong Provincial People's Hospital	marketed	Corticosteroid plus alkylating agent combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid plus alkylating agent combination class)

Guangdong Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). prednisone plus cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/prednisone-plus-cyclophosphamide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing